: J&J’s HIV vaccine fails Phase 3 clinical trial


Johnson & Johnson’s JNJ, -1.26% experimental HIV vaccine is safe but not effective, and the late-stage study will be discontinued as a result of that finding, federal researchers said Wednesday. J&J’s stock was down 1.1% in trading on Wednesday afternoon. The vaccine was being tested in a Phase 3 clinical trial that enrolled 3,900 men who have sex with men and transgender people in several countries, including the U.S. The National Institute of Allergy and Infectious Diseases provided funding for the trial. J&J’s stock is up 1.9% over the past year, while the S&P 500 SPX, -1.06% has declined 14.4%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Should I claim Social Security at 62 and invest it or wait until 70?
Next articleEconomic Report: U.S. industrial output falls sharply in December, sparking talk of factory ‘recession’


Please enter your comment!
Please enter your name here